17 apr: Europa/luk: Finanssektoren trak kraftigt op
18 apr: USA/aktier: Største stigninger i en måned
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
03 jul - 
Novo: Rival får godkendt Tresiba-konkurrent i Japan ..
02 jul - 
Aktier/middag: Mærsk tager revanche i stille marked ..
02 jul - 
Novo tror fortsat på Tresiba-fremtid i Tyskland ..
Relateret debat
03 jul - 
Tak for hjælpen Mackeith, nogen mennesker kan bar..
03 jul - 
Jeg forstår simpelthen ikke, hvad det er du mener..
03 jul - 
Grunden til at lpe123 mener at han er så vidende ..

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
30 jun
NOVO-B
Du formår aldrig at komme med et eneste argument for dine påstande, det er ærlig talt ved at være li..
10
02 jul
NOVO-B
Hold nu kæft hvor er i syge i potten.
7
30 jun
NOVO-B
Du SKAL absolut ikke læse alle thch's indlæg, hvis du ikke finder dem brugbare...   Jeg har selv ful..
3
02 jul
NOVO-B
Nej, han skrev jo netop det modsatte; men du vil bare ikke erkende at du ikke aner havd du taler om,..
2
02 jul
NOVO-B
Jo, han har netop forstået det helt rigtigt.   Du har bare ikke kendskab til hvad "Yellowing" betyde..
2
02 jul
NOVO-B
Det er vel ikke kun Novo der har det problem, og det er vel heller ikke noget nyt problem der lige p..
2
02 jul
NOVO-B
Snakker om MARKEDET Goodwrench.   Det er sgu lidt kedeligt at snakke om sig selv hele tiden.   Men h..
2
02 jul
NOVO-B
Man ved at markedet er ved at toppe når der sidder private og brokker sig over en aktie der er STEGE..
2
02 jul
NOVO-B
Fordi du ikke køber nok af dem 
2
03 jul
NOVO-B
Måske det ville hjælpe på din forståelse hvis du satte dig lidt ind i Lundbeck's problemer efterhånd..
1

Polaris/Partner: Rigtig god nyhed for Mols-Liniens fremtid

03-07-2015 16:23:03
Ligesom dens færger pendler frem og tilbage mellem Odden og Ebeltoft/Aarhus, er det også gået frem og tilbage for selve rederiet Mols-Linien. Men det er slut nu..

Vestas-rival napper havvindmøllekontrakt på 400 megewatt

03-07-2015 14:27:13
Franske Alstom har landet en ordre om at levere turbiner til vindmølleparken Merkur Offshore, der er en 400 megawatt vindmølleprojekt i de tyske farvande. Det s..

Aktier/middag: Pandora og Mærsk undgår græsk investorskjul

03-07-2015 11:36:53
Investorerne kryber lige så stille i skjul før weekendens afgørende folkeafstemning i Grækenland, og på det danske marked er det kun Pandora og Mærsk, der for a..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Novo Nordisk B A/S 368,70 -0,6% Fald i aktiekurs
Novo-Nordisk A/S 55,18 -0,5% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
4. juli 2015 23:45:30
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150702.1 - EUROWEB1 - 2015-07-04 23:45:30 - 2015-07-04 23:45:30 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x